Paper Details

  1. Home
  2. Paper Details

A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

Author: AlberighiO D, BordinG, CantiniF, CutoloM, DavoliC, DovigoL, FerraccioliG, LovinoC, MacchioniP, MarchesoniA, OlivieriI, PadulaA, PaseroG, SalaffiF, SalvaraniC

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Cyclosporine was more efficacious and well-tolerated than symptomatic therapy alone or sulfasalazine in the treatment of psoriatic arthritis.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the efficacy and tolerability of cyclosporine (CSA) with that of symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA). METHODS: Twelve rheumatology centers recruited 99 patients with active PsA in a 24 week, prospective, randomiz...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11669169

データ提供：米国国立医学図書館（NLM）

Cyclosporine: A Powerful Weapon Against Psoriatic Arthritis

Rheumatology, the study of joint diseases, continues to seek effective treatments for debilitating conditions such as psoriatic arthritis (PsA). This study compared the efficacy of cyclosporine (CSA) with sulfasalazine (SSZ) and symptomatic therapy (ST) in managing PsA. The research revealed that CSA demonstrated statistically significant improvements in pain, joint tenderness, and overall disease activity compared to both SSZ and ST. The results indicate that CSA may be a more effective treatment option for patients with PsA. This study sheds light on the potential for CSA to significantly impact the lives of individuals suffering from PsA, offering a path toward improved functionality and quality of life.

CSA: A Potential Game Changer for Psoriatic Arthritis Treatment

This study reveals that CSA is more effective than SSZ and ST in managing PsA, as demonstrated by significant improvements in pain, joint tenderness, and overall disease activity. This research emphasizes the potential of CSA as a valuable treatment option for PsA, providing a glimmer of hope for improved outcomes and reduced suffering for patients with this condition.

Navigating the Treatment Landscape

Individuals with PsA should consult with a rheumatologist to discuss the most appropriate treatment options for their specific needs and condition. While cyclosporine appears promising, it is important to consider individual factors such as potential side effects and overall health before deciding on treatment. This study underscores the importance of seeking professional guidance and tailoring treatment plans to achieve the best possible outcomes for each patient.

Dr.Camel's Conclusion

Like a skilled desert nomad navigating through a challenging landscape, this research guides us toward a better understanding of PsA treatment. Cyclosporine emerges as a promising option, potentially changing the treatment landscape for this debilitating condition. The study emphasizes the importance of individualized care and collaboration with a healthcare professional for effective disease management.

Date :
  1. Date Completed 2002-03-12
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

11669169

DOI: Digital Object Identifier

11669169

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.